Education
About Us
Working with TipRanks
Follow Us
Elekta AB (GB:0O5H)
LSE:0O5H
0O5H Stock Chart & Stats
kr56.70
-kr1.00(-1.60%)
At close: 4:00 PM EST
kr56.70
-kr1.00(-1.60%)
Day’s Range― - ―
52-Week Rangekr42.20 - kr66.60
Previous CloseN/A
Volume130.28K
Average Volume (3M)955.69K
Market Cap
kr21.51B
Enterprise Valuekr25.41B
Total Cash (Recent Filing)kr2.54B
Total Debt (Recent Filing)kr7.28B
Price to Earnings (P/E)546.4
Beta1.37
Next Earnings
Jun 03, 2026EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.88
Shares Outstanding368,587,650
10 Day Avg. Volume658,271
30 Day Avg. Volume955,692
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)2.13
Price to Sales (P/S)1.04
P/FCF Ratio17.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr60.00Price Target Upside5.82% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.26
Revenue Forecast (FY)kr16.91B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistent operating and free cash flow (~SEK 2.0B) shows the business converts sales into cash despite earnings pressure. This cash cushion supports R&D, service investment and debt servicing, enhancing durability over the next several quarters even if profits remain weak.
Recurring Service & Installed-base RevenueElekta’s business model includes high-margin recurring revenue from service contracts, upgrades and spare parts tied to its installed base. That annuity-like stream stabilizes cashflow and margins over time and underpins long-term customer relationships and upgrade cycles.
Durable Gross Margins From Core FranchiseThe company’s core radiation therapy systems and software sustain a ~38% gross margin, indicating structural product profitability. Even with EBIT pressure, healthy gross margins give room to absorb cost variability and protect long-term margin recovery as volumes normalize.
Bears Say
Earnings Deterioration And Margin CompressionShift from prior double-digit returns to a TTM net loss and compressed margins reflects structural pressures (costs, mix or non-op items). Sustained earnings weakness could impair reinvestment, slow R&D and limit ability to fund strategic initiatives over the coming 2–6 months.
Rising Leverage Reduces Balance-sheet FlexibilityLeverage rising to roughly 1.0 debt/equity and lower equity levels mean less financial flexibility. If profits don’t recover, higher debt load increases refinancing and interest risks and constrains capacity for acquisitions, large capex or aggressive share-return programs.
Negative Revenue Growth TrendTrailing revenue decline (-4.3%) signals weaker equipment orders or softer market demand. Continued top-line contraction threatens long-term service and upgrade revenue growth, undermining the installed-base expansion that drives recurring revenue and margin leverage.
Elekta AB News
0O5H FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest share price was kr42.20 and its highest was kr66.60 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is kr21.51B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Jun 03, 2026 which is in 72 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Mar 05, 2026. The company reported kr0.88 earnings per share for the quarter, beating the consensus estimate of kr0.489 by kr0.391.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Undervalued.
Does Elekta AB pay dividends?
Elekta AB does not currently pay dividends.
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate is 1.33.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of kr0.88 in its last earnings report, beating expectations of kr0.489. Following the earnings report the stock price went up 3.729%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in GB:0O5H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
0O5H Stock 12 Month Forecast
Average Price Target
kr60.00
▲(5.82% Upside)
Technical Analysis
Vitrolife AB
―
Camurus AB
―
RaySearch Laboratories AB
―
C-Rad AB Class B
―
MedCap AB
―
Options Prices
Currently, No data available
---